{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T05:02:34Z","timestamp":1789794154417,"version":"4.0.1"},"reference-count":105,"publisher":"Japan Atherosclerosis Society","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2026]]},"DOI":"10.5551\/jat.rv22061","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:11:30Z","timestamp":1789769490000},"source":"Crossref","is-referenced-by-count":0,"title":["HDL \u2013 Immune Cell Crosstalk in Autoimmune Diseases and its Role in Accelerated Atherosclerosis"],"prefix":"10.5551","author":[{"given":"Yasuhiro","family":"Endo","sequence":"first","affiliation":[{"name":"Faculty of Medical Technology, Niigata University of Pharmacy and Medical and Life Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsune","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Technology, Faculty of Medical Science, Juntendo University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Ikewaki","sequence":"additional","affiliation":[{"name":"Center for Preventive Medicine, The Jikei University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Galli M, Abbate A, Bonaca MP, Crea F, Forte M, Frati G, Gaudino M, Gibson CM, Gorog DA, Mehran R, Montone RA, O\u2019Donoghue ML, Steg PG, Sciarretta S, Angiolillo DJ: Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies. Nat Rev Cardiol, 2026","DOI":"10.1038\/s41569-026-01249-z"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ: Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med, 2017; 377: 1119-1131","DOI":"10.1056\/NEJMoa1707914"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, L\u00f3pez-Send\u00f3n J, Ostadal P, Koenig W, Angoulvant D, Gr\u00e9goire JC, Lavoie MA, Dub\u00e9 MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L\u2019Allier PL, Guertin MC, Roubille F: Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med, 2019; 381: 2497-2505","DOI":"10.1056\/NEJMoa1912388"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) von Eckardstein A, Nordestgaard BG, Remaley AT, Catapano AL: High-density lipoprotein revisited: biological functions and clinical relevance. Eur Heart J, 2023; 44: 1394-1407","DOI":"10.1093\/eurheartj\/ehac605"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) von Eckardstein A, Robert J: HDL Are Host Defense Lipoproteins. Circ Res, 2026; 138: e327426","DOI":"10.1161\/CIRCRESAHA.126.327426"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Conrad N, Verbeke G, Molenberghs G, Goetschalckx L, Callender T, Cambridge G, Mason JC, Rahimi K, McMurray JJV, Verbakel JY: Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet, 2022; 400: 733-743","DOI":"10.1016\/S0140-6736(22)01349-6"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Zimerman A, Kunzler ALF, Weber BN, Ran X, Murphy SA, Wang H, Honarpour N, Keech AC, Sever PS, Sabatine MS, Giugliano RP: Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial. Circulation, 2025; 151: 1467-1476","DOI":"10.1161\/CIRCULATIONAHA.124.072756"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, Gabriel SE: Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis, 2011; 70: 482-487","DOI":"10.1136\/ard.2010.135871"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Porsch F, Binder CJ: Autoimmune diseases and atherosclerotic cardiovascular disease. Nat Rev Cardiol, 2024; 21: 780-807","DOI":"10.1038\/s41569-024-01045-7"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Tejera-Segura B, Mac\u00eda-D\u00edaz M, Machado JD, de Vera-Gonz\u00e1lez A, Garc\u00eda-Dopico JA, Olmos JM, Hern\u00e1ndez JL, D\u00edaz-Gonz\u00e1lez F, Gonz\u00e1lez-Gay MA, Ferraz-Amaro I: HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis. Arthritis Res Ther, 2017; 19: 113","DOI":"10.1186\/s13075-017-1311-3"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) S\u00e1nchez-P\u00e9rez H, Quevedo-Abeledo JC, de Armas-Rillo L, Rua-Figueroa \u00cd, Tejera-Segura B, Armas-Gonz\u00e1lez E, Machado JD, Garc\u00eda-Dopico JA, Jimenez-Sosa A, Rodr\u00edguez-Lozano C, D\u00edaz-Gonz\u00e1lez F, Gonz\u00e1lez-Gay MA, Ferraz-Amaro I: Impaired HDL cholesterol efflux capacity in systemic lupus erythematosus patients is related to subclinical carotid atherosclerosis. Rheumatology (Oxford), 2020; 59: 2847-2856","DOI":"10.1093\/rheumatology\/keaa038"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Husaini ASA, Fathima A, Halawa D, Aakel N, Erre GL, Giordo R, Zayed H, Pintus G: Exploring endothelial dysfunction in major rheumatic diseases: current trends and future directions. J Mol Med (Berl), 2025; 103: 635-649","DOI":"10.1007\/s00109-025-02539-8"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) \u0141uczak A, Madej M, Kasprzyk A, Doroszko A: Role of the eNOS Uncoupling and the Nitric Oxide Metabolic Pathway in the Pathogenesis of Autoimmune Rheumatic Diseases. Oxid Med Cell Longev, 2020; 2020: 1417981","DOI":"10.1155\/2020\/1417981"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Xia H, Pan Z, Hong Y, Zhao Q, Fan W: A retrospective study on the correlation between antibody levels and endothelial function in SLE patients: An analysis based on ultrasound and serum biomarkers. Mol Immunol, 2025; 181: 66-74","DOI":"10.1016\/j.molimm.2025.02.018"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Mak A, Kow NY, Schwarz H, Gong L, Tay SH, Ling LH: Endothelial dysfunction in systemic lupus erythematosus - a case-control study and an updated meta-analysis and meta-regression. Sci Rep, 2017; 7: 7320","DOI":"10.1038\/s41598-017-07574-1"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Mendoza-Pinto C, Rojas-Villarraga A, Molano-Gonz\u00e1lez N, Garc\u00eda-Carrasco M, Mungu\u00eda-Realpozo P, Etchegaray-Morales I, Morales-S\u00e1nchez H, Berra-Romani R, Cervera R: Endothelial dysfunction and arterial stiffness in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Atherosclerosis, 2020; 297: 55-63","DOI":"10.1016\/j.atherosclerosis.2020.01.028"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Di Minno MN, Ambrosino P, Lupoli R, Di Minno A, Tasso M, Peluso R, Tremoli E: Clinical assessment of endothelial function in patients with rheumatoid arthritis: A meta-analysis of literature studies. Eur J Intern Med, 2015; 26: 835-842","DOI":"10.1016\/j.ejim.2015.10.016"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Mangoni AA, Zinellu A: A systematic review and meta-analysis of circulating adhesion molecules in rheumatoid arthritis. Inflamm Res, 2024; 73: 305-327","DOI":"10.1007\/s00011-023-01837-6"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Xia YR, Mao YM, Wang JP, Li QR, Fan YG, Pan HF, Ye DQ: Elevated Urinary and Blood Vascular Cell Adhesion Molecule-1 as Potential Biomarkers for Active Systemic Lupus Erythematosus: A Meta-analysis. Curr Pharm Des, 2020; 26: 5998-6006","DOI":"10.2174\/1381612826666200826135929"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Mangoni AA, Zinellu A: Circulating cell adhesion molecules in systemic sclerosis: a systematic review and meta-analysis. Front Immunol, 2024; 15: 1438302","DOI":"10.3389\/fimmu.2024.1438302"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Liu R, Yue Z, Peng X, Wang X, Feng Z, Wan L: Association Between Intercellular Adhesion Molecule-1, -2, -3 Plasma Levels and Disease Activity of Ankylosing Spondylitis in the Chinese Han Population. Spine (Phila Pa 1976), 2016; 41: E618-624","DOI":"10.1097\/BRS.0000000000001328"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Atehort\u00faa L, Rojas M, V\u00e1squez G, Mu\u00f1oz-Vahos CH, Vanegas-Garc\u00eda A, Posada-Duque RA, Casta\u00f1o D: Endothelial activation and injury by microparticles in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther, 2019; 21: 34","DOI":"10.1186\/s13075-018-1796-4"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Parker B, Al-Husain A, Pemberton P, Yates AP, Ho P, Gorodkin R, Teh LS, Alexander MY, Bruce IN: Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus. Ann Rheum Dis, 2014; 73: 1144-1150","DOI":"10.1136\/annrheumdis-2012-203028"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Matsuzawa Y, Kwon TG, Lennon RJ, Lerman LO, Lerman A: Prognostic Value of Flow-Mediated Vasodilation in Brachial Artery and Fingertip Artery for Cardiovascular Events: A Systematic Review and Meta-Analysis. J Am Heart Assoc, 2015; 4","DOI":"10.1161\/JAHA.115.002270"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, Post W, Lima JA, Crouse JR, Herrington DM: Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation, 2009; 120: 502-509","DOI":"10.1161\/CIRCULATIONAHA.109.864801"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Mortensen MB, Jensen JM, R\u00f8nnow Sand NP, Kragholm K, Blaha MJ, Grove EL, S\u00f8rensen HT, Olesen K, Maeng M, L\u00f8gstrup B, Busk M, Hauge EM, Navar AM, B\u00f8tker HE, N\u00f8rgaard BL: Association of Autoimmune Diseases With Coronary Atherosclerosis Severity and Ischemic Events. J Am Coll Cardiol, 2024; 83: 2643-2654","DOI":"10.1016\/j.jacc.2024.04.030"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Mineo C, Yuhanna IS, Quon MJ, Shaul PW: High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem, 2003; 278: 9142-9149","DOI":"10.1074\/jbc.M211394200"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Nofer JR, van der Giet M, T\u00f6lle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, G\u00f6decke A, Ishii I, Kleuser B, Sch\u00e4fers M, Fobker M, Zidek W, Assmann G, Chun J, Levkau B: HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest, 2004; 113: 569-581","DOI":"10.1172\/JCI200418004"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Ashby DT, Rye KA, Clay MA, Vadas MA, Gamble JR, Barter PJ: Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol, 1998; 18: 1450-1455","DOI":"10.1161\/01.ATV.18.9.1450"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Tabet F, Vickers KC, Cuesta Torres LF, Wiese CB, Shoucri BM, Lambert G, Catherinet C, Prado-Lourenco L, Levin MG, Thacker S, Sethupathy P, Barter PJ, Remaley AT, Rye KA: HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nat Commun, 2014; 5: 3292","DOI":"10.1038\/ncomms4292"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Nofer JR, Levkau B, Wolinska I, Junker R, Fobker M, von Eckardstein A, Seedorf U, Assmann G: Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem, 2001; 276: 34480-34485","DOI":"10.1074\/jbc.M103782200"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Ruiz M, Okada H, Dahlb\u00e4ck B: HDL-associated ApoM is anti-apoptotic by delivering sphingosine 1-phosphate to S1P1 &amp; S1P3 receptors on vascular endothelium. Lipids Health Dis, 2017; 16: 36","DOI":"10.1186\/s12944-017-0429-2"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Noor R, Shuaib U, Wang CX, Todd K, Ghani U, Schwindt B, Shuaib A: High-density lipoprotein cholesterol regulates endothelial progenitor cells by increasing eNOS and preventing apoptosis. Atherosclerosis, 2007; 192: 92-99","DOI":"10.1016\/j.atherosclerosis.2006.06.023"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Hesse B, Rovas A, Buscher K, Kusche-Vihrog K, Brand M, Di Marco GS, Kielstein JT, Pavenst\u00e4dt H, Linke WA, Nofer JR, K\u00fcmpers P, Lukasz A: Symmetric dimethylarginine in dysfunctional high-density lipoprotein mediates endothelial glycocalyx breakdown in chronic kidney disease. Kidney Int, 2020; 97: 502-515","DOI":"10.1016\/j.kint.2019.10.017"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Huang L, Chambliss KL, Gao X, Yuhanna IS, Behling-Kelly E, Bergaya S, Ahmed M, Michaely P, Luby-Phelps K, Darehshouri A, Xu L, Fisher EA, Ge WP, Mineo C, Shaul PW: SR-B1 drives endothelial cell LDL transcytosis via DOCK4 to promote atherosclerosis. Nature, 2019; 569: 565-569","DOI":"10.1038\/s41586-019-1140-4"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Terasaka N, Yu S, Yvan-Charvet L, Wang N, Mzhavia N, Langlois R, Pagler T, Li R, Welch CL, Goldberg IJ, Tall AR: ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. J Clin Invest, 2008; 118: 3701-3713","DOI":"10.1172\/JCI35470"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Wilkerson BA, Argraves KM: The role of sphingosine-1-phosphate in endothelial barrier function. Biochim Biophys Acta, 2014; 1841: 1403-1412","DOI":"10.1016\/j.bbalip.2014.06.012"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Jia C, Anderson JLC, Gruppen EG, Lei Y, Bakker SJL, Dullaart RPF, Tietge UJF: High-Density Lipoprotein Anti-Inflammatory Capacity and Incident Cardiovascular Events. Circulation, 2021; 143: 1935-1945","DOI":"10.1161\/CIRCULATIONAHA.120.050808"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Ronda N, Favari E, Borghi MO, Ingegnoli F, Gerosa M, Chighizola C, Zimetti F, Adorni MP, Bernini F, Meroni PL: Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis, 2014; 73: 609-615","DOI":"10.1136\/annrheumdis-2012-202914"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Gkolfinopoulou C, Stratikos E, Theofilatos D, Kardassis D, Voulgari PV, Drosos AA, Chroni A: Impaired Antiatherogenic Functions of High-density Lipoprotein in Patients with Ankylosing Spondylitis. J Rheumatol, 2015; 42: 1652-1660","DOI":"10.3899\/jrheum.141532"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Ferraz-Amaro I, Hernandez-Hernandez MV, Armas-Gonzalez E, Sanchez-Perez H, Machado JD, Diaz-Gonzalez F: HDL cholesterol efflux capacity is related to disease activity in psoriatic arthritis patients. Clin Rheumatol, 2020; 39: 1871-1880","DOI":"10.1007\/s10067-020-04961-4"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Ferraz-Amaro I, Delgado-Frias E, Hernandez-Hernandez V, Sanchez-Perez H, de Armas-Rillo L, Armas-Gonzalez E, Machado JD, Diaz-Gonzalez F: HDL cholesterol efflux capacity and lipid profile in patients with systemic sclerosis. Arthritis Res Ther, 2021; 23: 62","DOI":"10.1186\/s13075-021-02443-9"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW: HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med, 2014; 371: 2383-2393","DOI":"10.1056\/NEJMoa1409065"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ: Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med, 2011; 364: 127-135","DOI":"10.1056\/NEJMoa1001689"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Ishikawa T, Ayaori M, Uto-Kondo H, Nakajima T, Mutoh M, Ikewaki K: High-density lipoprotein cholesterol efflux capacity as a relevant predictor of atherosclerotic coronary disease. Atherosclerosis, 2015; 242: 318-322","DOI":"10.1016\/j.atherosclerosis.2015.06.028"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Ogura M, Hori M, Harada-Shiba M: Association Between Cholesterol Efflux Capacity and Atherosclerotic Cardiovascular Disease in Patients With Familial Hypercholesterolemia. Arterioscler Thromb Vasc Biol, 2016; 36: 181-188","DOI":"10.1161\/ATVBAHA.115.306665"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Ormseth MJ, Yancey PG, Solus JF, Bridges SL, Jr., Curtis JR, Linton MF, Fazio S, Davies SS, Roberts LJ, 2nd, Vickers KC, Kon V, Michael Stein C: Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis. Arthritis Rheumatol, 2016; 68: 2099-2105","DOI":"10.1002\/art.39675"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Holzer M, Wolf P, Curcic S, Birner-Gruenberger R, Weger W, Inzinger M, El-Gamal D, Wadsack C, Heinemann A, Marsche G: Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res, 2012; 53: 1618-1624","DOI":"10.1194\/jlr.M027367"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Kennedy MA, Barrera GC, Nakamura K, Bald\u00e1n A, Tarr P, Fishbein MC, Frank J, Francone OL, Edwards PA: ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab, 2005; 1: 121-131","DOI":"10.1016\/j.cmet.2005.01.002"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Ji Y, Jian B, Wang N, Sun Y, Moya ML, Phillips MC, Rothblat GH, Swaney JB, Tall AR: Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem, 1997; 272: 20982-20985","DOI":"10.1074\/jbc.272.34.20982"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Oram JF, Lawn RM, Garvin MR, Wade DP: ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem, 2000; 275: 34508-34511","DOI":"10.1074\/jbc.M006738200"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, Seilhamer JJ, Vaughan AM, Oram JF: The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest, 1999; 104: R25-31","DOI":"10.1172\/JCI8119"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Zewinger S, Drechsler C, Kleber ME, Dressel A, Riffel J, Triem S, Lehmann M, Kopecky C, S\u00e4emann MD, Lepper PM, Silbernagel G, Scharnagl H, Ritsch A, Thorand B, de las Heras Gala T, Wagenpfeil S, Koenig W, Peters A, Laufs U, Wanner C, Fliser D, Speer T, M\u00e4rz W: Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. Eur Heart J, 2015; 36: 3007-3016","DOI":"10.1093\/eurheartj\/ehv352"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Han CY, Tang C, Guevara ME, Wei H, Wietecha T, Shao B, Subramanian S, Omer M, Wang S, O\u2019Brien KD, Marcovina SM, Wight TN, Vaisar T, de Beer MC, de Beer FC, Osborne WR, Elkon KB, Chait A: Serum amyloid A impairs the antiinflammatory properties of HDL. J Clin Invest, 2016; 126: 266-281","DOI":"10.1172\/JCI83475"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Smith CK, Vivekanandan-Giri A, Tang C, Knight JS, Mathew A, Padilla RL, Gillespie BW, Carmona-Rivera C, Liu X, Subramanian V, Hasni S, Thompson PR, Heinecke JW, Saran R, Pennathur S, Kaplan MJ: Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus. Arthritis Rheumatol, 2014; 66: 2532-2544","DOI":"10.1002\/art.38703"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Vivekanandan-Giri A, Slocum JL, Byun J, Tang C, Sands RL, Gillespie BW, Heinecke JW, Saran R, Kaplan MJ, Pennathur S: High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis. Ann Rheum Dis, 2013; 72: 1725-1731","DOI":"10.1136\/annrheumdis-2012-202033"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Shao B, Pennathur S, Heinecke JW: Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions. J Biol Chem, 2012; 287: 6375-6386","DOI":"10.1074\/jbc.M111.337345"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Shao B, Tang C, Sinha A, Mayer PS, Davenport GD, Brot N, Oda MN, Zhao XQ, Heinecke JW: Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ Res, 2014; 114: 1733-1742","DOI":"10.1161\/CIRCRESAHA.114.303454"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Gao D, Ashraf MZ, Zhang L, Kar N, Byzova TV, Podrez EA: Cross-linking modifications of HDL apoproteins by oxidized phospholipids: structural characterization, <i>in vivo<\/i> detection, and functional implications. J Biol Chem, 2020; 295: 1973-1984","DOI":"10.1074\/jbc.RA119.008445"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) P\u00e9rez-Baos S, Barrasa JI, Gratal P, Larra\u00f1aga-Vera A, Prieto-Potin I, Herrero-Beaumont G, Largo R: Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis. Br J Pharmacol, 2017; 174: 3018-3031","DOI":"10.1111\/bph.13932"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Botta EE, Pierini F, Martin M, Cerda O, Lozano Chiappe E, Citera G, Davico B, Gandino I, Tetzlaff W, Mero\u00f1o T, S\u00e1ez MS, Yanez A, Goff WL, Rosa J, Kontush A, G\u00f3mez Rosso L, Soriano ER, Brites F: Modifications on lipid profile and high-density lipoprotein function related to treatment with tofacitinib in female patients with rheumatoid arthritis: Impact of previous therapy with biological agents. J Clin Lipidol, 2025; 19: 659-669","DOI":"10.1016\/j.jacl.2025.02.013"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Swanson KV, Deng M, Ting JP: The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol, 2019; 19: 477-489","DOI":"10.1038\/s41577-019-0165-0"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Riksen NP, Bekkering S, Mulder WJM, Netea MG: Trained immunity in atherosclerotic cardiovascular disease. Nat Rev Cardiol, 2023; 20: 799-811","DOI":"10.1038\/s41569-023-00894-y"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Zhao TX, Mallat Z: Targeting the Immune System in Atherosclerosis: JACC State-of-the-Art Review. J Am Coll Cardiol, 2019; 73: 1691-1706","DOI":"10.1016\/j.jacc.2018.12.083"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Bartoloni E, Cacciapaglia F, Erre GL, Gremese E, Manfredi A, Piga M, Sakellariou G, Spinelli FR, Viapiana O, Atzeni F: Immunomodulation for accelerated atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Autoimmun Rev, 2025; 24: 103760","DOI":"10.1016\/j.autrev.2025.103760"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Jin M, Fang J, Wang JJ, Shao X, Xu SW, Liu PQ, Ye WC, Liu ZP: Regulation of toll-like receptor (TLR) signaling pathways in atherosclerosis: from mechanisms to targeted therapeutics. Acta Pharmacol Sin, 2023; 44: 2358-2375","DOI":"10.1038\/s41401-023-01123-5"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Zhu X, Owen JS, Wilson MD, Li H, Griffiths GL, Thomas MJ, Hiltbold EM, Fessler MB, Parks JS: Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. J Lipid Res, 2010; 51: 3196-3206","DOI":"10.1194\/jlr.M006486"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Yin K, Chen WJ, Zhou ZG, Zhao GJ, Lv YC, Ouyang XP, Yu XH, Fu Y, Jiang ZS, Tang CK: Apolipoprotein A-I inhibits CD40 proinflammatory signaling via ATP-binding cassette transporter A1-mediated modulation of lipid raft in macrophages. J Atheroscler Thromb, 2012; 19: 823-836","DOI":"10.5551\/jat.12823"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Funes SC, Rios M, Escobar-Vera J, Kalergis AM: Implications of macrophage polarization in autoimmunity. Immunology, 2018; 154: 186-195","DOI":"10.1111\/imm.12910"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Peng Y, Zhou M, Yang H, Qu R, Qiu Y, Hao J, Bi H, Guo D: Regulatory Mechanism of M1\/M2 Macrophage Polarization in the Development of Autoimmune Diseases. Mediators Inflamm, 2023; 2023: 8821610","DOI":"10.1155\/2023\/8821610"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Zhang X, Deng X, Wei S, Li M, Zeng X: Effects of Metabolic Dysregulation on Macrophage Polarization in Rheumatoid Arthritis. Arthritis Rheumatol, 2026","DOI":"10.1002\/art.70253"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Lee MK, Moore XL, Fu Y, Al-Sharea A, Dragoljevic D, Fernandez-Rojo MA, Parton R, Sviridov D, Murphy AJ, Chin-Dusting JP: High-density lipoprotein inhibits human M1 macrophage polarization through redistribution of caveolin-1. Br J Pharmacol, 2016; 173: 741-751","DOI":"10.1111\/bph.13319"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Li Z, Guo J, Bi L: Role of the NLRP3 inflammasome in autoimmune diseases. Biomed Pharmacother, 2020; 130: 110542","DOI":"10.1016\/j.biopha.2020.110542"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Westerterp M, Fotakis P, Ouimet M, Bochem AE, Zhang H, Molusky MM, Wang W, Abramowicz S, la Bastide-van Gemert S, Wang N, Welch CL, Reilly MP, Stroes ES, Moore KJ, Tall AR: Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis. Circulation, 2018; 138: 898-912","DOI":"10.1161\/CIRCULATIONAHA.117.032636"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) D\u00f6ring Y, Libby P, Soehnlein O: Neutrophil Extracellular Traps Participate in Cardiovascular Diseases: Recent Experimental and Clinical Insights. Circ Res, 2020; 126: 1228-1241","DOI":"10.1161\/CIRCRESAHA.120.315931"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Ohinata H, Obama T, Makiyama T, Watanabe Y, Itabe H: High-Density Lipoprotein Suppresses Neutrophil Extracellular Traps Enhanced by Oxidized Low-Density Lipoprotein or Oxidized Phospholipids. Int J Mol Sci, 2022; 23","DOI":"10.3390\/ijms232213992"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Carmona-Rivera C, Kaplan MJ: Low-density granulocytes in systemic autoimmunity and autoinflammation. Immunol Rev, 2023; 314: 313-325","DOI":"10.1111\/imr.13161"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Xia D, Zheng Q, Liu Y, Wang L, Wei D: Targeting Immune Cell Metabolism: A Promising Therapeutic Approach for Cardiovascular Disease. Immunology, 2025; 175: 134-150","DOI":"10.1111\/imm.13913"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Atehortua L, Davidson WS, Chougnet CA: Interactions Between HDL and CD4+ T Cells: A Novel Understanding of HDL Anti-Inflammatory Properties. Arterioscler Thromb Vasc Biol, 2024; 44: 1191-1201","DOI":"10.1161\/ATVBAHA.124.320851"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Bazioti V, La Rose AM, Maassen S, Bianchi F, de Boer R, Halmos B, Dabral D, Guilbaud E, Flohr-Svendsen A, Groenen AG, Marmolejo-Garza A, Koster MH, Kloosterhuis NJ, Havinga R, Pranger AT, Langelaar-Makkinje M, de Bruin A, van de Sluis B, Kohan AB, Yvan-Charvet L, van den Bogaart G, Westerterp M: T cell cholesterol efflux suppresses apoptosis and senescence and increases atherosclerosis in middle aged mice. Nat Commun, 2022; 13: 3799","DOI":"10.1038\/s41467-022-31135-4"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Tiniakou I, Drakos E, Sinatkas V, Van Eck M, Zannis VI, Boumpas D, Verginis P, Kardassis D: High-density lipoprotein attenuates Th1 and th17 autoimmune responses by modulating dendritic cell maturation and function. J Immunol, 2015; 194: 4676-4687","DOI":"10.4049\/jimmunol.1402870"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Gaddis DE, Padgett LE, Wu R, McSkimming C, Romines V, Taylor AM, McNamara CA, Kronenberg M, Crotty S, Thomas MJ, Sorci-Thomas MG, Hedrick CC: Apolipoprotein AI prevents regulatory to follicular helper T cell switching during atherosclerosis. Nat Commun, 2018; 9: 1095","DOI":"10.1038\/s41467-018-03493-5"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) D\u00f6ring Y, Manthey HD, Drechsler M, Lievens D, Megens RT, Soehnlein O, Busch M, Manca M, Koenen RR, Pelisek J, Daemen MJ, Lutgens E, Zenke M, Binder CJ, Weber C, Zernecke A: Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation, 2012; 125: 1673-1683","DOI":"10.1161\/CIRCULATIONAHA.111.046755"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Gal\u00e1n M, Fern\u00e1ndez-M\u00e9ndez L, N\u00fa\u00f1ez V, Femen\u00eda-Mui\u00f1a M, Figuera-Belmonte P, Moya-Ruiz E, Mart\u00ednez-Cano S, Hern\u00e1ndez-Garc\u00eda E, Rodrigo-Tapias M, Rodr\u00edguez-Ronchel A, Rela\u00f1o-Rup\u00e9rez C, Wculek SK, Benguria A, Dopazo A, Henri S, Jo S, Liu TT, Malissen B, Murphy KM, Ramiro AR, Carregal-Romero S, Ruiz-Cabello J, Robles-Vera I, Sancho D: cDC1s Promote Atherosclerosis via Local Immunity and Are Targetable for Therapy. Circ Res, 2025; 137: 400-416","DOI":"10.1161\/CIRCRESAHA.124.325792"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Wang SH, Yuan SG, Peng DQ, Zhao SP: HDL and ApoA-I inhibit antigen presentation-mediated T cell activation by disrupting lipid rafts in antigen presenting cells. Atherosclerosis, 2012; 225: 105-114","DOI":"10.1016\/j.atherosclerosis.2012.07.029"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) Chung CP, Oeser A, Raggi P, Sokka T, Pincus T, Solus JF, Linton MF, Fazio S, Stein CM: Lipoprotein subclasses determined by nuclear magnetic resonance spectroscopy and coronary atherosclerosis in patients with rheumatoid arthritis. J Rheumatol, 2010; 37: 1633-1638","DOI":"10.3899\/jrheum.090639"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D, Park G, McMahon M, Paulus HE, Fogelman AM, Reddy ST: Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum, 2009; 60: 2870-2879","DOI":"10.1002\/art.24802"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Karpouzas GA, Papotti B, Ormseth SR, Palumbo M, Hernandez E, Adorni MP, Zimetti F, Budoff MJ, Ronda N: ATP-binding cassette G1 membrane transporter-mediated cholesterol efflux capacity influences coronary atherosclerosis and cardiovascular risk in Rheumatoid Arthritis. J Autoimmun, 2023; 136: 103029","DOI":"10.1016\/j.jaut.2023.103029"},{"key":"89","unstructured":"89) Oliviero F, Sfriso P, Baldo G, Dayer JM, Giunco S, Scanu A, Bernardi D, Ramonda R, Plebani M, Punzi L: Apolipoprotein A-I and cholesterol in synovial fluid of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Clin Exp Rheumatol, 2009; 27: 79-83"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Garcia-Gomez C, Nolla JM, Valverde J, Narvaez J, Corbella E, Pinto X: High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. Eur J Clin Invest, 2008; 38: 686-692","DOI":"10.1111\/j.1365-2362.2008.01994.x"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Juarez-Rojas J, Medina-Urrutia A, Posadas-Sanchez R, Jorge-Galarza E, Mendoza-Perez E, Caracas-Portilla N, Cardoso-Saldana G, Munoz-Gallegos G, Posadas-Romero C: High-density lipoproteins are abnormal in young women with uncomplicated systemic lupus erythematosus. Lupus, 2008; 17: 981-987","DOI":"10.1177\/0961203308093072"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) Dedemadi AG, Gkolfinopoulou C, Nikoleri D, Nikoloudaki M, Ruhanen H, Holopainen M, Kakela R, Christopoulou G, Bournazos S, Constantoulakis P, Sidiropoulos P, Bertsias G, Chroni A: Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment. Rheumatology (Oxford), 2025; 64: 648-657","DOI":"10.1093\/rheumatology\/keae192"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) McMahon M, Grossman J, Skaggs B, Fitzgerald J, Sahakian L, Ragavendra N, Charles-Schoeman C, Watson K, Wong WK, Volkmann E, Chen W, Gorn A, Karpouzas G, Weisman M, Wallace DJ, Hahn BH: Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum, 2009; 60: 2428-2437","DOI":"10.1002\/art.24677"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Mehta NN, Li R, Krishnamoorthy P, Yu Y, Farver W, Rodrigues A, Raper A, Wilcox M, Baer A, DerOhannesian S, Wolfe M, Reilly MP, Rader DJ, VanVoorhees A, Gelfand JM: Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis, 2012; 224: 218-221","DOI":"10.1016\/j.atherosclerosis.2012.06.068"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95) Holzer M, Wolf P, Inzinger M, Trieb M, Curcic S, Pasterk L, Weger W, Heinemann A, Marsche G: Anti-psoriatic therapy recovers high-density lipoprotein composition and function. J Invest Dermatol, 2014; 134: 635-642","DOI":"10.1038\/jid.2013.359"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Salahuddin T, Natarajan B, Playford MP, Joshi AA, Teague H, Masmoudi Y, Selwaness M, Chen MY, Bluemke DA, Mehta NN: Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis. Eur Heart J, 2015; 36: 2662-2665","DOI":"10.1093\/eurheartj\/ehv339"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97) Mehta NN, Shin DB, Joshi AA, Dey AK, Armstrong AW, Duffin KC, Fuxench ZC, Harrington CL, Hubbard RA, Kalb RE, Menter A, Rader DJ, Reilly MP, Simpson EL, Takeshita J, Torigian DA, Werner TJ, Troxel AB, Tyring SK, Vanderbeek SB, Van Voorhees AS, Playford MP, Ahlman MA, Alavi A, Gelfand JM: Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial. Circ Cardiovasc Imaging, 2018; 11: e007394","DOI":"10.1161\/CIRCIMAGING.117.007394"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Wolk R, Armstrong EJ, Hansen PR, Thiers B, Lan S, Tallman AM, Kaur M, Tatulych S: Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis. J Clin Lipidol, 2017; 11: 1243-1256","DOI":"10.1016\/j.jacl.2017.06.012"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99) Lu YT, Zhang ZL, Zhou XY, Zhang D, Tian T, Fan P, Zhang Y, Zhou XL: Predicting stroke and myocardial infarction risk in Takayasu arteritis with automated machine learning models. iScience, 2023; 26: 108421","DOI":"10.1016\/j.isci.2023.108421"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100) Wang Z, Dang A, Lv N: Brachial-Ankle Pulse Wave Velocity is Increased and Associated with Disease Activity in Patients with Takayasu Arteritis. J Atheroscler Thromb, 2020; 27: 172-182","DOI":"10.5551\/jat.48447"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101) Zang Q, Li F, Ju Y, Wang J, Luo J, Liu W, Ding T, He L, Mo L: Dysregulated serum lipid profile and atherosclerosis in untreated female Takayasu arteritis patients: a propensity score-matched analysis. Scand J Rheumatol, 2025; 54: 302-310","DOI":"10.1080\/03009742.2025.2488096"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102) Khojah A, Morgan G, Kadakia A, Klein-Gitelman MS, Pachman LM: Dyslipidemia in Juvenile Dermatomyositis. Sci Rep, 2024; 14: 26528","DOI":"10.1038\/s41598-024-77985-4"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103) Le Goff W, Peng DQ, Settle M, Brubaker G, Morton RE, Smith JD: Cyclosporin A traps ABCA1 at the plasma membrane and inhibits ABCA1-mediated lipid efflux to apolipoprotein A-I. Arterioscler Thromb Vasc Biol, 2004; 24: 2155-2161","DOI":"10.1161\/01.ATV.0000144811.94581.52"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104) Bouillet B, Gautier T, Denimal D, Samson M, Masson D, Pais de Barros JP, Maquart G, Xolin M, Grosfeld A, Dalle H, Verg\u00e8s B, Moldes M, F\u00e8ve B: Glucocorticoids impair HDL-mediated cholesterol efflux besides increased HDL cholesterol concentration: a proof of concept. Eur J Endocrinol, 2020; 183: 297-306","DOI":"10.1530\/EJE-20-0477"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105) Kim SY, Yu M, Morin EE, Kang J, Kaplan MJ, Schwendeman A: High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy. Arthritis Rheumatol, 2020; 72: 20-30","DOI":"10.1002\/art.41059"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/advpub\/0\/advpub_RV22061\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:33:01Z","timestamp":1789792381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/advpub\/0\/advpub_RV22061\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":105,"URL":"https:\/\/doi.org\/10.5551\/jat.rv22061","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"RV22061"}}